
Javier Saez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1187458/publications.pdf Version: 2024-02-01



INVIED SAFZ

#	Article	IF	CITATIONS
1	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients. International Journal of Molecular Sciences, 2022, 23, 7522.	4.1	3
2	Tau phosphorylation by glycogen synthase kinase 3β modulates enzyme acetylcholinesterase expression. Journal of Neurochemistry, 2021, 157, 2091-2105.	3.9	17
3	Plasma ACE2 species are differentially altered in COVIDâ€19 patients. FASEB Journal, 2021, 35, e21745.	0.5	18
4	The apolipoprotein receptor LRP3 compromises APP levels. Alzheimer's Research and Therapy, 2021, 13, 181.	6.2	9
5	Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 96.	6.2	24
6	α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 139.	6.2	13
7	Elevated Plasma Reelin Levels in Children With Autism. Frontiers in Psychiatry, 2020, 11, 242.	2.6	8
8	Characterization of Cerebrospinal Fluid BACE1 Species. Molecular Neurobiology, 2019, 56, 8603-8616.	4.0	4
9	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	1.1	9
10	Measurement of CSF αâ€synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease. Journal of Neurochemistry, 2019, 150, 218-230.	3.9	12
11	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. Clinica Chimica Acta, 2019, 490, 6-11.	1.1	3
12	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	4.4	11
13	Inhibition of Î ³ -Secretase Leads to an Increase in Presenilin-1. Molecular Neurobiology, 2018, 55, 5047-5058.	4.0	19
14	Decreased generation of Câ€ŧerminal fragments of ApoER2 and increased reelin expression in Alzheimer's disease. FASEB Journal, 2018, 32, 3536-3546.	0.5	23
15	Levels of ADAM10 are reduced in Alzheimer's disease CSF. Journal of Neuroinflammation, 2018, 15, 213.	7.2	39
16	HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain. Molecular Neurobiology, 2017, 54, 188-199.	4.0	13
17	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	3.3	28
18	Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2017, 57, 1281-1291.	2.6	4

#	Article	IF	CITATIONS
19	Neuromuscular Junction Impairment in Amyotrophic Lateral Sclerosis: Reassessing the Role of Acetylcholinesterase. Frontiers in Molecular Neuroscience, 2016, 9, 160.	2.9	49
20	The β-amyloid peptide compromises Reelin signaling in Alzheimer's disease. Scientific Reports, 2016, 6, 31646.	3.3	44
21	Reelin in Alzheimer's Disease, Increased Levels but Impaired Signaling: When More is Less. Journal of Alzheimer's Disease, 2016, 52, 403-416.	2.6	30
22	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. Molecular Neurodegeneration, 2016, 11, 66.	10.8	9
23	Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2016, 53, 831-841.	2.6	26
24	Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimerââ,¬â"¢s Disease. Frontiers in Neurology, 2015, 6, 125.	2.4	15
25	Heteromers of amyloid precursor protein in cerebrospinal fluid. Molecular Neurodegeneration, 2015, 10, 2.	10.8	22
26	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
27	Quantification of the Transcripts Encoding Different Forms of AChE in Various Cell Types: Real-Time PCR Coupled with Standards in Revealing the Copy Number. Journal of Molecular Neuroscience, 2014, 53, 461-468.	2.3	9
28	Acetylcholinesterase Protein Level Is Preserved in the Alzheimer's Brain. Journal of Molecular Neuroscience, 2014, 53, 446-453.	2.3	20
29	Acetylcholinesterase Modulates Presenilin-1 Levels and Î ³ -Secretase Activity. Journal of Alzheimer's Disease, 2014, 41, 911-924.	2.6	22
30	ApoER2 processing by presenilinâ€1 modulates reelin expression. FASEB Journal, 2014, 28, 1543-1554.	0.5	29
31	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. Neurobiology of Aging, 2014, 35, 1526-1536.	3.1	9
32	P2-115: CEREBROSPINAL FLUID PRESENILIN-1 COMPLEXES: A POTENTIAL BIOMARKER FOR ALZHEIMER'S DISEASE. , 2014, 10, P513-P513.		0
33	P3-037: THE B-AMYLOID PEPTIDE COMPROMISES REELIN SIGNALING IN ALZHEIMER'S DISEASE. , 2014, 10, P641-P641.		0
34	CSF Presenilin-1 complexes are increased in Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 46.	5.2	22
35	Beta-Amyloid Impairs Reelin Signaling. PLoS ONE, 2013, 8, e72297.	2.5	40
36	Identification of a 31-bp Deletion in the RELN Gene Causing Lissencephaly with Cerebellar Hypoplasia in Sheep. PLoS ONE, 2013, 8, e81072.	2.5	12

#	Article	IF	CITATIONS
37	Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiology of Aging, 2012, 33, 624.e23-624.e34.	3.1	24
38	Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. Neurobiology of Aging, 2012, 33, 627.e27-627.e37.	3.1	23
39	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
40	Readthrough Acetylcholinesterase Is Increased in Human Liver Cirrhosis. PLoS ONE, 2012, 7, e44598.	2.5	25
41	Revisiting the role of acetylcholinesterase in Alzheimer's disease: cross-talk with P-tau and β-amyloid. Frontiers in Molecular Neuroscience, 2011, 4, 22.	2.9	208
42	β-amyloid controls altered Reelin expression and processing in Alzheimer's disease. Neurobiology of Disease, 2010, 37, 682-691.	4.4	53
43	Altered Levels of Acetylcholinesterase in Alzheimer Plasma. PLoS ONE, 2010, 5, e8701.	2.5	93
44	Association between acetylcholinesterase and β-amyloid peptide in Alzheimer's cerebrospinal fluid. Chemico-Biological Interactions, 2008, 175, 209-215.	4.0	25
45	Reelin is overexpressed in the liver and plasma of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with cirrhosis. International Journal of Biochemistry and Cell Biology, 2008, 40, 766-775.	2.8	27
46	Presenilin 1 Interacts with Acetylcholinesterase and Alters Its Enzymatic Activity and Glycosylation. Molecular and Cellular Biology, 2008, 28, 2908-2919.	2.3	26
47	Brain cholinergic impairment in liver failure. Brain, 2008, 131, 2946-2956.	7.6	88
48	Alzheimer's Disease and Reelin. , 2008, , 401-409.		1
49	Glutamate-induced activation of nitric oxide synthase is impaired in cerebral cortexinÂvivoin rats with chronic liver failure. Journal of Neurochemistry, 2007, 102, 51-64.	3.9	35
50	Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer?s disease. Journal of Neurochemistry, 2007, 101, 1701-1711.	3.9	28
51	Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. Journal of Neurochemistry, 2006, 96, 97-104.	3.9	34
52	Altered Glycosylation of Acetylcholinesterase in the Creutzfeldt-Jakob Cerebrospinal Fluid. Journal of Molecular Neuroscience, 2006, 30, 65-66.	2.3	14
53	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. Hepatology, 2006, 43, 444-453.	7.3	38
54	Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. Hepatology, 2006, 43, 1257-1266.	7.3	147

#	Article	IF	CITATIONS
55	Nogo-A Expression in the Human Hippocampus in Normal Aging and in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 433-444.	1.7	62
56	Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5573-5578.	7.1	196
57	Intraperitoneal administration of 340kDa human plasma butyrylcholinesterase increases the level of the enzyme in the cerebrospinal fluid of rats. Neuroscience Letters, 2005, 383, 93-98.	2.1	4
58	Bile duct ligation plus hyperammonemia in rats reproduces the alterations in the modulation of soluble guanylate cyclase by nitric oxide in brain of cirrhotic patients. Neuroscience, 2005, 130, 435-443.	2.3	22
59	P3-384 Decreased level and altered glycosylation of acetylcholinesterase in creutzfeld-jakob lumbar cerebrospinal fluid. Neurobiology of Aging, 2004, 25, S464-S465.	3.1	Ο
60	Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with β-amyloid peptides. Brain Research, 2003, 965, 283-286.	2.2	25
61	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 132-136.	2.9	69
62	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 520-526.	2.9	55
63	Acetylcholinesterase level and molecular isoforms are altered in brain of Reelin Orleans mutant mice. Journal of Neurochemistry, 2003, 87, 773-779.	3.9	5
64	Acetylcholinesterase activation in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. Neuroscience Letters, 2003, 348, 123-125.	2.1	13
65	Acetylcholinesterase activity and molecular isoform distribution are altered after focal cerebral ischemia. Molecular Brain Research, 2003, 117, 240-244.	2.3	15
66	Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid β-peptide. Neuroscience Letters, 2002, 325, 199-202.	2.1	31
67	Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. Journal of Neurochemistry, 2002, 81, 441-448.	3.9	41
68	Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma. Neuroscience, 2001, 107, 199-208.	2.3	14
69	Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease. Journal of Alzheimer's Disease, 2001, 3, 323-328.	2.6	13
70	Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in alzheimer's disease. Brain Research, 2001, 889, 247-250.	2.2	17
71	Wheat germ agglutininâ€binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. Journal of Neurochemistry, 2001, 79, 1022-1026.	3.9	39
72	An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease. Acta Neurologica Scandinavica, 2000, 102, 49-52.	2.1	19

#	Article	IF	CITATIONS
73	Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 664-667.	1.9	36
74	Caspase-3 activation by \hat{l}^2 -amyloid and prion protein peptides is independent from their neurotoxic effect. Neuroscience Letters, 2000, 293, 207-210.	2.1	31
75	Inhibition of neurite outgrowth from chick sympathetic neurons by cholinesterase inhibitors is not mediated by binding to cholinesterases. Neuroscience Letters, 1999, 266, 77-80.	2.1	7
76	Characterization of molecular forms of acetyl- and butyrylcholinesterase in human acoustic neurinomas. Neuroscience Letters, 1999, 274, 56-60.	2.1	10
77	Molecular Isoform Distribution and Glycosylation of Acetylcholinesterase Are Altered in Brain and Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Neurochemistry, 1999, 72, 1600-1608.	3.9	99
78	Acetylcholinesterase Is Increased in the Brains of Transgenic Mice Expressing the Câ€Terminal Fragment (CT100) of the βâ€Amyloid Protein Precursor of Alzheimer's Disease. Journal of Neurochemistry, 1998, 71, 723-731.	3.9	92
79	Expression and Glycosylation of Acetylcholinesterase in Alzheimer's Disease Brain. , 1998, , 175-179.		0
80	Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet, The, 1997, 350, 929.	13.7	38
81	The Amyloid βâ€Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells. Journal of Neurochemistry, 1997, 69, 1177-1184.	3.9	112
82	Molecular forms of acetyl- and butyrylcholinesterase in human glioma. Neuroscience Letters, 1996, 206, 173-176.	2.1	20
83	Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1317, 210-218.	3.8	22
84	Monomers and dimers of acetylcholinesterase in human meningioma are anchored to the membrane by glycosylphosphatidylinositol. Neuroscience Letters, 1995, 195, 101-104.	2.1	16
85	Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. Journal of Neuroscience Research, 1993, 35, 678-689.	2.9	45
86	Ricinus communis agglutinin I reacting and non-reacting butyrylcholinesterase in human cerebrospinal fluid. Neuroscience Letters, 1992, 145, 59-62.	2.1	20